Diseases requiring laparoscopic cholecystectomy such as gallbladder stones and gallbladder polyps
Conditions
Interventions
Electroacupuncture Group (T Group).:Disposable sterile acupuncture needles (Huatuo brand, 0.30 × 25 mm and 0.30 × 40 mm) were inserted through the adhesive pads into the acupoints, and after deqi was
Sham electroacupuncture group (N group).:In Group N, after routine disinfection of the acupoint sites, adhesive pads were applied, and blunt-tipped placebo needles with a similar appearance were place
Control group (C group).:Group C received neither acupuncture nor electroacupuncture treatment.
Sponsors
Tianjin Nankai Hospital
Eligibility
Sex/Gender
All
Age
16 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18–75 years, with no restrictions on sex or ethnicity; 2. Patients scheduled to undergo elective laparoscopic cholecystectomy for gallstones or gallbladder polyps; 3. Patients and their family members agreed to participate in this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who did not meet the age requirement; 2. Patients with a history of severe underlying primary diseases involving the cardiovascular, pulmonary, nervous, or coagulation systems; 3. Patients with cerebrovascular or cardiovascular events, pulmonary inflammation, or vascular embolism in the lower extremities or lungs; 4. Patients who refused electroacupuncture, or who had skin infection or ulceration at the stimulation acupoint sites; 5. Patients with a history of acute pancreatitis; 6. Patients with a history of chronic diarrhea; 7. Patients with a history of gastrointestinal surgery; 8. Patients with common bile duct dilatation or common bile duct stones detected on imaging examination; 9. Patients with obstructive jaundice; 10. Patients with psychiatric disorders; 11. Patients who had received acupuncture treatment (manual acupuncture, electroacupuncture, or transcutaneous electrical acupoint stimulation) within 30 days before enrollment; 12. Patients who were unable to cooperate or whom the investigators considered unsuitable for participation in this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of postoperative gastrointestinal dysfunction, including abdominal pain, abdominal distension, diarrhea, nausea/vomiting, and loss of appetite; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative visual analog scale (VAS) pain score;The Short-From-36 Health Survey,SF-36;HR;MAP;Propofol usage;remifentanil usage;Surgical time;intraoperative haemorrhage;Time to first bowel gas passage;Time to first postoperative defecation;blood count;liver and kidney function;PCT;Serum C-reactive protein (CRP); | — |
Countries
China
Contacts
Public ContactYu Jianbo
Tianjin Nankai Hospital
Outcome results
None listed